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INTRODUCTION
Ulcerative colitis (UC) is a chronic relapsing and remitting in-
flammatory disease of the colon.1 Biologic therapy with tumor 
necrosis factor alpha (TNF-α) inhibitors, such as infliximab (IFX) 
and adalimumab (ADA), is currently the most effective treat-
ment for inducing and maintaining clinical remission in pa-
tients with moderate to severe UC, and has been reported to 
reduce the risk of hospitalization and surgery.2 IFX and ADA 
were approved for patients with UC in South Korea in 2010 
and 2013, respectively. Considering the differences in the mo-
lecular constructs, routes of administration, and dosing inter-
vals of these two TNF-α inhibitors, there may be differences in 
efficacy. However, although randomized clinical trials (RCTs) 
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pitalizations, and corticosteroid use between IFX and ADA users. Our findings indicate that IFX and ADA have comparable effec-
tiveness in biologic-naïve Korean patients with UC.
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have demonstrated that IFX and ADA are superior to placebo 
in the treatment of UC,3,4 there have been no head-to-head 
comparison trials of these two agents. As such, the need to un-
derstand the relative effectiveness of these two agents has re-
mained unmet, and decisions on the choice of TNF-α inhibitor 
have primarily been based on the preferences of the patients 
and clinicians.
An indirect comparison meta-analysis previously suggested 
that IFX is more effective than ADA in inducing remission, re-
sponse, and mucosal healing at 8 weeks, although these two 
agents exhibited comparable efficacy after 52 weeks of main-
tenance treatment in patients with UC.5 Another network me-
ta-analysis showed no difference in the induction and main-
tenance of remission and response between IFX and ADA in 
patients with UC.6 Additionally, a recent network meta-analysis 
revealed no difference in the rates of hospitalization and colec-
tomy for UC between IFX and ADA.7 However, these results 
are from indirect comparisons rather from direct comparisons. 
Moreover, prior network meta-analysis studies are limited by 
a lack of head-to-head trials, a small number of registration tri-
als, short follow-up (within 54 weeks), and restricted inclusion 
criteria in registration trials.
Although several observational studies have compared 
clinical outcomes between IFX and ADA in patients with UC, 
their results were inconsistent.8-13 Furthermore, most of the pre-
vious studies on this topic were performed in Western coun-
tries.8-13 Despite the increasing number of patients with UC in 
Asia,14,15 data on the comparative effectiveness of IFX and ADA 
in Asian patients are extremely scarce. Therefore, we conduct-
ed a nationwide population-based study to compare the effi-
cacy of IFX and ADA in biologic-naïve Korean patients with UC 
using a health claims administrative database. To better evalu-
ate the real-world outcomes of these two biologics, we com-
pared clinically important outcomes, including colectomy, 
emergency room (ER) visits, hospitalizations, and need for cor-
ticosteroids.
MATERIALS AND METHODS
Data source
The South Korean government operates a mandatory nation-
wide insurance system (National Health Insurance, NHI); there-
fore, all information about health-care utilization is registered 
in a comprehensive database, which is operated by the Health 
Insurance Review and Assessment Service (HIRA). The NHI 
provides mandatory universal health insurance covering all 
forms of health-care utilization, including outpatient care, 
pharmaceutical services, and hospitalization. Medical institu-
tions electronically submit health-care use information to en-
sure reimbursement, and this information is integrated into the 
HIRA claims database, which covers the entire population of 
South Korea (approximately 51 million people). The HIRA da-
tabase contains information on all patients, including demo-
graphic characteristics, ambulatory care history, principal di-
agnosis, and comorbidities, according to International 
Classification of Diseases 10th revision (ICD-10) codes, pre-
scriptions, and diagnostic or surgical procedures.16-18 The 
source population for this study was derived from NHI claims 
data from 2008 to 2016.
Patient identification and data capture
To improve the diagnostic accuracy of UC, only patients with 
data on both appropriate diagnostic codes and UC-related 
medicine prescriptions were selected.16-18 The ICD-10 codes 
K51.0–51.9 indicate UC. UC-related medicine prescriptions 
were defined as prescriptions of 5-aminosalicylic acid (ASA) 
for ≥1 month, immunomodulators (azathioprine or 6-mer-
captopurine) at least once, and/or biologics at least once.16-18 To 
rule out the use of drugs for other autoimmune diseases, these 
medications were confined to prescriptions received from a 
gastroenterology clinic. During the study period, the biologics 
approved for the treatment of UC in South Korea were IFX, 
ADA, and golimumab. However, the actual use of golimumab 
was very rare during the study period because this biologic was 
approved only in May 2015. Therefore, in this study, golimumab 
could not be compared with IFX and ADA.
The date of UC registration in the HIRA database was con-
sidered the date of diagnosis. Given that previous prevalent 
cases could confound the incidence rate, we set a washout pe-
riod of 2 years; therefore, we were able to analyze patients with 
UC diagnosed from January 1, 2010, to December 31, 2016. Pa-
tients in whom the first line of biologics was golimumab, those 
who were exposed to both IFX and ADA, and those with a his-
tory of colectomy before starting biologic therapy were exclud-
ed from the analysis.
The primary outcomes of interest were colectomy, ER visits, 
hospitalizations, and need for corticosteroids after the first use 
of biologics. Colectomy was identified using the procedural 
code. ER visits were defined as patient visits to the ER with UC 
as the primary diagnosis. Hospitalization was defined as admis-
sion for ≥3 days in the department of gastroenterology. Finally, 
new corticosteroid use was defined as moderate- to high-dose 
corticosteroid use (≥30 mg prednisolone, ≥50 mg methylpred-
nisolone, or ≥200 mg hydrocortisone) after 2 months of the first 
prescription of biologics.
Statistical analysis
The incidence rates of colectomy, ER visits, hospitalizations, 
and need for corticosteroids were calculated per 100 person-
years, and 95% confidence intervals (CIs) for the incidence 
rate were estimated using a Poisson distribution. For each 
group, the crude risk of outcomes was described using the Ka-
plan-Meier method and log-rank test. We used Cox proportion-
al hazard models to adjust for potential confounding variables. 
Baseline covariates, including sex, the period from UC diagno-
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sis to first biologics use, age, region, hospital scale, and steroid 
use at the time of first biologics use, were adjusted as time-fixed 
covariates. The use periods of cumulative biologics and con-
comitant medications, including 5-ASA and immunomodula-
tors, were adjusted as time-dependent covariates.
We further performed a sensitivity analysis on patients who 
used biologics for ≥6 months and a stratified analysis based 
on the use of TNF-α inhibitor monotherapy or combination 
therapy with immunomodulators (concomitant use of immu-
nomodulators). Concomitant use of immunomodulators was 
defined as prescriptions within 30 days before and/or after the 
start date of biologics. The results are presented as hazard ratios 
(HRs) with corresponding 95% CIs. All analyses were performed 
using the SAS Enterprise Guide (SAS Institute Inc., Cary, NC, 
USA), and p<0.05 was considered statistically significant.
Ethical considerations
All identifiable personal information in medical records was 
de-identified to comply with the Health Insurance Portability 
and Accountability Act. In addition, as the information in the 
HIRA database is encrypted, the database does not contain 
personal identifiers. The protocol of this study was approved by 
the Institutional Review Board of Severance Hospital, Yonsei 
University College of Medicine (IRB No. 4-2017-0927).
 
RESULTS
Patient characteristics
We identified 17167 patients who were diagnosed with UC be-
tween 2010 and 2016, of whom 1125 started their first TNF-α in-
hibitors during the study period. Of these 1125 patients, 57, 194, 
and 12 were excluded because of the use of golimumab, the 
use of both IFX and ADA, and a history of colectomy before 
the start of biologics, respectively. Ultimately, 862 patients 
were included in the study, of whom 630 were treated with IFX 
and 232 were treated with ADA (Fig. 1). The median follow-up 
period after starting TNF-α inhibitors was 1.8 years (interquar-
tile range, 0.8–3.3 years).
Table 1 shows the comparison of the baseline characteris-
tics of IFX users and ADA users. Sex, age at UC diagnosis, and 
age and hospital scale at first biologics use were not different 
between IFX users and ADA users. The mean period from UC 
diagnosis to first biologics use was shorter in IFX users than in 
ADA users (1.8±1.5 years vs. 2.4±1.6 years, p<0.001), whereas 
the mean period of biologics use was longer in IFX users than 
in ADA users (1.7±1.5 years vs. 1.2±0.9 years, p<0.001). During 
the follow-up period, 429 (68.1%) of 630 IFX users continued 
IFX therapy, and 183 (78.9%) of 232 ADA users continued 
ADA therapy. The rate of steroid use at the time of first biologics 
use was higher in IFX users than in ADA users (51.3% vs. 27.6%, 
p<0.001), whereas the rate of concomitant immunomodulator 
use was not different between IFX users and ADA users (63.5% 
vs. 58.6%, p=0.219).
Comparative effectiveness of ADA vs. IFX
There were no significant differences in the cumulative proba-
bilities of colectomy (p=0.459) (Fig. 2A), ER visits (p=0.086) (Fig. 
2B), and hospitalizations (p=0.809) (Fig. 2C). At 1 and 3 years 
Table 1. Baseline Characteristics of the Study Population
Characteristics
IFX users
(n=630)
ADA users
(n=232)
p value
Male sex 399 (63.3) 146 (62.9) 0.977
Age at diagnosis of UC (yr) 37.6±16.1 39.1±16.3 0.229
Age at first biologics use (yr) 39.4±16.2 41.5±16.4 0.093
Period from UC diagnosis to first 
  biologics use (yr)
1.8±1.5 2.4±1.6 <0.001
Period of biologics use (yr) 1.7±1.5 1.2±0.9 <0.001
<6 months 160 (25.4)   65 (28.0) 0.491
≥6 months 470 (74.6) 167 (72.0)
Region at first biologics use 0.030
Seoul 293 (46.5)   88 (37.9)
Outside Seoul 337 (53.5) 144 (62.1)
Hospital scale at first biologics use 0.102
Tertiary hospital 456 (72.4) 154 (66.4)
General hospital/ 
  community hospital/clinic
174 (27.6)   78 (33.6)
Medication use at first biologics use
5-ASA 411 (65.2) 155 (66.8) 0.726
Steroids 323 (51.3)   64 (27.6) <0.001
Immunomodulators 285 (45.2)   99 (42.7) 0.552
Concomitant immunomodulators 
  (±30 days) 0.219
No 230 (36.5)   96 (41.4)
Yes 400 (63.5) 136 (58.6)
IFX, infliximab; ADA, adalimumab; UC, ulcerative colitis; 5-ASA, 5-aminosali-
cylic acid.
Data are presented as a number (%) or mean±standard deviation.
Fig. 1. Flowchart of the identification of biologic-naïve patients with UC. UC, 
ulcerative colitis; IFX, infliximab; ADA, adalimumab.
51 million people in Korean National Health Insurance database
17167 new UC patients identified between 2010–2016
1125 UC patients used biologics
862 UC patients 
(630 IFX users and 232 ADA users)
Exclusion (n=263)
- Patients whose first line of biologics was golimumab (n=57)
-  Patients who were exposed to both IFX and ADA (n=194)
- Patients who had colectomy prior to first use of biologics (n=12)
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after the start of the first biologics, the cumulative rates of col-
ectomy were 0.7% and 1.1%, respectively, for IFX users and 0% 
and 2.7%, respectively, for ADA users. The number of patients 
who underwent colectomy during the follow-up period was 5 
among IFX users and 2 among ADA users. The surgical proce-
dure codes for these patients were as follows: Q2671 right or left 
hemicolectomy (one IFX user and one ADA user), Q2672 total 
colectomy (three IFX users and one ADA user), and QA925 to-
tal coloproctectomy with ileostomy (one IFX user). Meanwhile, 
the cumulative rates of ER visits at 1 and 3 years were 3.7% and 
5.8%, respectively, for IFX users and 4.5% and 11.8%, respec-
tively, for ADA users. For hospitalization, the cumulative rates 
at 1 and 3 years were 25.1% and 35.1%, respectively, for IFX us-
ers and 18.5% and 32.7%, respectively, for ADA users. Even af-
ter adjustment for confounding variables, there were no sig-
nificant differences in the risk of colectomy (HR, 1.87; 95% 
CI, 0.30–11.63), ER visits (HR, 1.58; 95% CI, 0.79–3.16), and hos-
pitalizations (HR, 0.83; 95% CI, 0.59–1.17) between the two 
groups (Table 2).
The cumulative probability of corticosteroid use was higher 
in ADA users than in IFX users (p=0.040) (Fig. 2D). However, this 
significant difference disappeared after adjusting for confound-
ing variables (HR, 1.16; 95% CI, 0.76–1.78) (Table 2).
Sensitivity analysis and stratified analysis
In a sensitivity analysis restricted to patients who used biolog-
ics for ≥6 months, we also observed no significant differences 
in the risk of colectomy (HR, 7.61; 95% CI, 0.85–67.92), ER vis-
its (HR, 1.49; 95% CI, 0.66–3.37), hospitalizations (HR, 0.89; 
95% CI, 0.61–1.31), and corticosteroid use (HR, 1.18; 95% CI, 
0.74–1.90) between IFX users and ADA users (Table 2). Addi-
tionally, on stratified analysis, there were no significant differ-
ences in the risk of ER visits, hospitalizations, and corticoste-
roid use between IFX users and ADA users with either TNF-α 
1.00
0.75
0.50
0.25
0.00
1.00
0.75
0.50
0.25
0.00
1.00
0.75
0.50
0.25
0.00
1.00
0.75
0.50
0.25
0.00
0             1             2             3             4             5             6            7
0             1             2             3             4             5             6            7
0             1             2             3             4             5             6            7
0             1             2             3             4             5             6            7
Time (yr)
Time (yr)
Time (yr)
Time (yr)
Survival rate (%)
Year 1 Year 2 Year 3 Year 4 Year 5 Year 6
IFX   99.3 99.3 98.9 98.9 98.9 98.9
ADA 100.0 97.3 97.3 97.3 - -
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Year 1 Year 2 Year 3 Year 4 Year 5 Year 6
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Fig. 2. Survival free of (A) colectomy, (B) emergency room visit, (C) hospitalization, and (D) new corticosteroid use. IFX, infliximab; ADA, adalimumab.
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inhibitor monotherapy or combination therapy (Table 3).
DISCUSSION
In this nationwide population-based study of 862 biologic-na-
ïve Korean patients with UC, we found that IFX and ADA were 
comparable in terms of the risk of colectomy, UC-related ER 
visits, UC-related hospitalizations, and new initiation of corti-
costeroids. These results were stable even when only patients 
who used biologics for ≥6 months were analyzed. Additionally, 
these results were unchanged in patients treated with biologic 
monotherapy or those treated with combination therapy with 
immunomodulators. Our findings indicate that IFX and ADA 
elicit comparable effects on UC-related, clinically important, 
real-world outcomes.
Most studies on the comparative outcomes of IFX and ADA 
in UC have been conducted in Western countries, and data on 
this topic in Asian countries are extremely scarce. Our results are 
consistent with the results from prior Western studies. Although 
our study could not compare the rates of induction and main-
tenance of remission between IFX and ADA, several Western 
observational studies have reported no difference in clinical re-
mission and response between these two drugs. A retrospective 
study performed in the United States including biologic-naïve 
IFX-treated (n=424) and ADA-treated (n=380) patients with UC 
showed no significant differences in time to remission, no rec-
tal bleeding, normal stool count, and normal physician global 
assessment.9 In a Canadian single-center cohort study involv-
ing 53 patients with UC, the responses to induction and main-
Table 3. Comparative Effectiveness of ADA vs. IFX in Biologics-Naïve Patients with UC Stratified according to Use of TNF-α Inhibitor Monotherapy and 
Concomitant Immunomodulatory Therapy
Outcomes
TNF-α inhibitor monotherapy (n=326) TNF-α inhibitor+immunomodulatory therapy (n=536)
Adjusted HR (95% CI)*
(ADA vs. IFX)
p value
Adjusted HR (95% CI)*
(ADA vs. IFX)
p value
Overall biologics users
Colectomy -† -   3.06 (0.43–22.09) 0.267
UC-related ER visit 1.33 (0.42–4.19) 0.624 1.73 (0.73–4.13) 0.215
UC-related hospitalization 0.65 (0.36–1.19) 0.160 0.94 (0.62–1.43) 0.771
New steroid use (after 2 months) 1.07 (0.54–2.10) 0.848 1.23 (0.71–2.15) 0.459
Biologics users for ≥6 months
Colectomy -† -   8.00 (0.86–74.68) 0.068
UC-related ER visit 0.64 (0.13–3.23) 0.586 2.10 (0.79–5.58) 0.138
UC-related hospitalization 0.60 (0.29–1.23) 0.164 1.06 (0.68–1.67) 0.794
New steroid use (after 2 months) 0.94 (0.42–2.12) 0.888 1.39 (0.77–2.50) 0.270
IFX, infliximab; ADA, adalimumab; TNF-α, tumor necrosis factor-α; HR, hazard ratio; CI, confidence interval; UC, ulcerative colitis; ER, emergency room.
*Adjusted for sex, age, region, and hospital scale at first biologics use; cumulative biologics use period; medication (5-aminosalicylic acid, immunomodulators, 
and steroids) use; and the period from UC diagnosis to first biologics use; †Results were not estimated because of patients who underwent TNF-α inhibitor 
monotherapy, only one in the overall biologics user group and none in the biologics user for ≥6 months group later underwent colectomy.
Table 2. Comparative Effectiveness of ADA vs. IFX in Biologics-Naïve Patients with UC
Outcomes
ADA IFX ADA vs. IFX
Number 
of events
Incidence rate, 
per 100 py (95% CI)
Number 
of events
Incidence rate, 
per 100 py (95% CI)
Adjusted HR
(95% CI)*
p value
Overall biologics users
Colectomy   2 0.6 (0.1–1.9)     5 0.3 (0.1–0.7) 1.87 (0.30–11.63) 0.505
UC-related ER visit 13 4.1 (2.3–6.8)   35 2.3 (1.6–3.1) 1.58 (0.79–3.16) 0.192
UC-related hospitalization 44 16.4 (12.0–21.8) 189 17.1 (14.8–19.6) 0.83 (0.59–1.17) 0.283
New steroid use (after 2 months) 31 10.9 (7.5–15.2)   94 7.0 (5.7–8.5) 1.16 (0.76–1.78) 0.498
Biologics users for ≥6 months
Colectomy   2 0.7 (0.1–2.2)     2 0.2 (0.03–0.5) 7.61 (0.85–67.92) 0.069
UC-related ER visit   9 3.3 (1.6–5.9)   24 2.0 (1.3–2.8) 1.49 (0.66–3.37) 0.338
UC-related hospitalization 36 15.8 (11.2–21.5) 140 15.3 (12.9–17.9) 0.89 (0.61–1.31) 0.558
New steroid use (after 2 months) 26 10.7 (7.1–15.4)   75 7.0 (5.5–8.7) 1.18 (0.74–1.90) 0.480
IFX, infliximab; ADA, adalimumab; py, person-years; CI, confidence interval; HR, hazard ratio; UC, ulcerative colitis; ER, emergency room.
*Adjusted for sex, age, region, and hospital scale at first biologics use; cumulative biologics use period; medication (5-aminosalicylic acid, immunomodulators, 
and steroids) use; and the period from UC diagnosis to first biologics use.
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tenance therapy were similar between IFX and ADA.13 Re-
cently, a Japanese study involving 25 biologic-naïve patients 
with UC also demonstrated no statistical differences in clinical 
response, remission, mucosal healing, and steroid-free remis-
sion rates at weeks 14 and 54 between IFX users (n=10) and 
ADA users (n=15).19
In addition, similar to our findings, some Western studies 
have reported no difference in the risk of surgery, hospitaliza-
tion, and steroid utilization between IFX and ADA users. In a 
US study conducted at two tertiary referral academic centers, 
there were no differences in UC-related surgery, hospitaliza-
tions, or prednisone prescription within 1 year after the initia-
tion of IFX (n=337) or ADA (n=82).8 An Italian population-
based cohort study using health administrative databases also 
revealed that the risk of steroid utilization did not differ between 
469 IFX and 91 ADA new users with UC.12 Furthermore, con-
sistent with these results, an indirect comparison through a re-
cent network meta-analysis showed no difference in the rates 
of UC-related hospitalization and colectomy between IFX and 
ADA, although only two RCTs were included in this network 
meta-analysis.7
However, a few Western studies showed different results 
from those of our study. In a US administrative claims-based 
study of 1400 patients with UC who were new users of TNF-α 
inhibitors, there were no significant differences in the risk of 
all-cause or UC-related hospitalization and serious infections 
between IFX- and ADA-treated patients; however, the need for 
corticosteroid use was lower in IFX-treated than in ADA-treated 
patients.10 In this study, the risk of surgery was low in both IFX- 
and ADA-treated patients, and the number of surgical events 
was very small, precluding meaningful analysis.10 In contrast, 
a nationwide population-based study of 1719 biologics-naïve 
patients with UC in Denmark demonstrated that the risks of sur-
gery and new corticosteroid initiation were comparable among 
IFX users and ADA users; however, ADA was associated with a 
higher risk of all-cause hospitalization and serious infections, 
and showed a trend toward a higher risk of UC-related hospi-
talization, compared with IFX.11 Although the results of these 
two studies are not identical, these results may suggest that IFX 
may be more beneficial than ADA in the treatment of UC. In 
line with these results, two network meta-analyses also indi-
cated the superiority of IFX over ADA in patients with UC.20,21 A 
network meta-analysis by Danese, et al.20 showed the superior-
ity of IFX over ADA in both inducing and maintaining remis-
sion in UC. Recently, another network meta-analysis by Chol-
apranee, et al.21 revealed that ADA was inferior to IFX in inducing 
mucosal healing in UC. However, the results of these network 
meta-analyses are indirect comparisons based on comparison 
trials of “IFX vs. placebo” and “ADA vs. placebo,” rather than 
head-to-head comparisons.
Although the reason for the difference between our findings 
and those from some Western studies cannot be clearly eluci-
dated, there may be a few potential explanations. First, al-
though IFX and ADA have similar mechanisms of action in 
targeting TNF-α, there are subtle differences in pharmacoki-
netics, which may explain the difference in efficacy. The dose 
of IFX administered intravenously is determined based on 
body weight, whereas ADA administered subcutaneously is a 
fixed-dose drug that does not take body weight into consider-
ation. This may result in a difference in bioavailability. The prev-
alence of obesity is relatively lower in Korea than in the United 
States and Europe.22 More specifically, the data from the Orga-
nization for Economic Cooperation and Development showed 
that the prevalence of obesity defined by body mass index (BMI) 
≥30 kg/m2 among individuals older than 15 years was the high-
est in the United States at 38.2% and the second lowest in Ko-
rea at 5.3% in 2017.22 Although there are no data on the preva-
lence of obesity in Korean patients with UC, it is expected to be 
lower than the prevalence of obesity in US patients with inflam-
matory bowel disease (IBD), reported as 18–33%.23-25 ADA, a 
fixed-dose drug, may be advantageous for non-obese patients, 
but disadvantageous for obese patients, considering only the 
drug effect. Indeed, a prior study reported that higher BMI in 
patients with IBD is predictive of dose escalation during ADA 
treatment.26 Additionally, a retrospective cohort study demon-
strated a higher need for dose escalation due to early loss of re-
sponse in obese patients with Crohn’s disease treated with ADA, 
but not in those treated with IFX.27 Moreover, another study 
observed a trend toward a lower trough level in ADA-treated 
patients with a BMI of >30 kg/m2.28 The relatively lower BMI in 
Korean patients than in Western patients may have helped 
overcome the disadvantage of ADA bioavailability. Second, in 
our clinical practice, patients with more severe disease may 
have been preferentially prescribed IFX rather than ADA. This 
may cause bias in the results against IFX because more severe 
patients with a higher risk for surgery and hospitalization may 
be more likely to be prescribed IFX. Actually, in our study, the 
rate of steroid utilization at the first biologics use was higher in 
patients initiated on IFX than in those initiated on ADA (51.3% 
vs. 27.6%). However, this factor was adjusted for in our analy-
sis. Lastly, as the phenotype and genetic susceptibility of IBD 
differ between Western and Asian patients,14,29 the efficacy of 
IFX or ADA may vary depending on race and ethnicity.
This is the first nationwide population-based study to com-
pare the real-life outcomes of IFX and ADA in Korean patients 
with UC. Nevertheless, our findings should be interpreted with 
caution, taking into account the limitations associated with 
the study design. First, this was a retrospective, claims-based, 
and observational study. Accordingly, information on disease 
severity and phenotypes, such as the extent of UC, were unavail-
able; thus, confounding factors that can affect clinical out-
comes could not be considered. Second, the efficacy of IFX 
and ADA in clinical responses or endoscopic responses, such 
as mucosal healing, could not be compared because informa-
tion on clinical and endoscopic activity was not available. Third, 
safety outcomes, such as serious or opportunistic infections, 
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were not evaluated. Fourth, because ADA was approved for pa-
tients with UC in South Korea on July 2013, there was a limita-
tion in assessing the long-term outcomes of ADA. Fifth, the im-
pact of dose escalation or interval shortening, which may 
influence clinical outcomes, was not assessed. Sixth, we did not 
verify the diagnostic accuracy of UC. However, considering that 
this study included only patients who used IFX or ADA and 
that these TNF-α inhibitors are approved only for UC patients 
with moderate to severe activity (Mayo score 6 to 12 and en-
doscopy subscore ≥2) in South Korea, it seems very unlikely 
that non-UC patients would have been misdiagnosed as hav-
ing UC. Lastly, we did not investigate factors contributing to 
preferences for IFX or ADA. A previous Korean study reported 
that the most influential reason for choosing IFX was “doctor’s 
presence” and that for ADA was “ease of use.”30 The study also 
demonstrated that having a >60-minute travel time to the hos-
pital was a significant independent predictive factor for ADA 
preference.30 
Despite these limitations, our study provides a better under-
standing of the real-world outcomes of IFX and ADA in Korean 
patients with UC. In this administrative claims-based study, 
we found no significant differences in four clinically important 
outcomes, including colectomy, ER visits, hospitalizations, and 
corticosteroid use, between IFX users and ADA users. These 
results suggest that IFX and ADA have comparable effective-
ness in biologic-naïve patients with UC. In the absence of RCTs 
with which to directly compare these two TNF-α inhibitors, our 
study suggests that for Korean patients with UC, deciding on 
either IFX or ADA can be based the preference of the patients 
and/or their clinicians.
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